Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05712889 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer
A Phase 1 study, sponsored by Vincerx Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT05712889 is a Phase 1 study that has completed, run by Vincerx Pharma. The registered enrollment target is 29 participants.
The verdict
NCT05712889, a Phase 1 study, has completed, sponsored by Vincerx Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
Determine the safety, tolerability, and maximum tolerated dose (MTD) of IV administered VIP236 as monotherapy in patients with advanced solid tumor cancer
Interventions
- DRUG VIP236 (Q3W)
- DRUG VIP236 (Q2W)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2023-01-24 |
| Est. Completion | 2024-10-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05712889
The ClinicalTrials.gov registry entry for NCT05712889 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vincerx Pharma, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which VIP236 (Q3W) is the first listed.
NCT05712889 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05712889 about?
NCT05712889 is a clinical study titled "Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer". Determine the safety, tolerability, and maximum tolerated dose (MTD) of IV administered VIP236 as monotherapy in patients with advanced solid tumor cancer
What is the current status of trial NCT05712889?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2023-01-24. Estimated completion is 2024-10-10.
What interventions are being tested in trial NCT05712889?
The interventions under investigation include: VIP236 (Q3W) (DRUG), VIP236 (Q2W) (DRUG).
Who is sponsoring clinical trial NCT05712889?
This trial is sponsored by Vincerx Pharma, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.